TRIAL DETAIL

Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Drug:
Trial Name:
Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
NCT#:
Conditions:
Solid Tumors
Status:
Terminated
Phase:
1
Start Date 10/01/2011
Age of Trial (yrs) 10.2
Treatment Phase:
Gleevec-resistant
Drug Category:
PI3K/mTOR inhibitor + MEK inhibitor + TOPO-1 inhibitor
Strategy:
Block related tumor signal paths
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
B1271002
Sponsor:
Pfizer
Patient Contact:
Pfizer CT.gov Call Center 1-800-718-1021 Pfizer Oncology Clinical Trial Information Service 1-877-369-9753 PfizerCancerTrials@emergingmed.com
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral Intravenous
Trial Notes:
Purpose: After the second protocol amendment two study arms are evaluated in this clinical protocol: PD-0325901 (MEK inhibitor) plus PF-05212384 (PI3K/mTOR inhibitor) and PF-05212384 plus irinotecan. The study will assess safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer. Once the maximum tolerated doses are identified, further assessment of these combinations will be done in patients with previously treated metastatic colorectal cancer or pancreatic cancer for the PF-05212384 plus irinotecan arm and in patients with KRAS mutated colorectal cancer for the combination of PF-05212384 plus PD-0325901

Trial Links

 

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
10945 Le Conte Ave.
Los Angeles
CA
90095
USA
1665 N. Ursula St.
Aurora
CO
80045
USA
610 University Ave
Toronto
ON
M5G 2M9
Canada
119-129
Barcelona
08035
Spain
Milan
20132
Italy
2020 Santa Monica Boulevard Suite 600
Santa Monica
CA
90404
USA
Charleston
SC
29425
USA